This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a ...

Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Semaglutide, the diabetes drug at the center of a global boom in weight-loss treatments, has entered the Moroccan market through a partnership between Danish pharmaceutical company Novo Nordisk and ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Novo Nordisk said Wednesday it has agreed to the U.S. Inflation Reduction Act’s (IRA) negotiated maximum fair prices for ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...